The limitations of traditional Herceptin treatment for invasive bladder cancer highlight the importance of seeking alternative strategies that can effectively target tumors with heterogeneous HER2 expression (Jiang et al., 2020). This evidence concerns the gene ERBB2 and urinary bladder carcinoma.